
Welcome to the
February edition of the JITC digest. The journal continues to grow and
thrive, publishing impactful research across the entire spectrum of the diverse
and interdisciplinary immunotherapy field. The articles in this month's digest
highlight innovative approaches to overcoming longstanding challenges in cancer
immunotherapy, and will surely spark important conversations moving forward.
I'm thrilled to
report that this month's digest features three papers from one of the journal's
new sections, Immune cell therapies and immune cell engineering—a
burgeoning area that continues to push boundaries in terms of advancing
scientific understanding and improving patient outcomes.
The highlighted articles
feature somewhat "outside-the-box" cell therapy strategies, two of
which could have exciting implications for the treatment of solid tumors. In
elegant preclinical models, Rahul Suresh et al. demonstrate robust
anti-tumor activity by adoptively transferred gene-edited immature myeloid
cells. In a different tactic, the feasibility of generating PD-1-deficient
effector memory T cells specific for melanoma antigens was demonstrated by
Lucine Marotte and colleagues.
Although cell
therapies have a well-established role in the treatment of hematologic
malignancies, relapse remains common. In an attempt to improve outcomes,
Benjamin Derman et al. demonstrate two effective strategies to
significantly reduce and delay T regulatory cell recovery after autologous stem
cell transplant in a pilot study of 15 patients with multiple myeloma.
In addition to the
exciting articles in the cell therapy section, be sure to read the paper by
Shibin Qu et al., describing a novel approach to tumor ablation that
causes the release of non-denatured neoantigens and damage-associated molecular
patterns capable of potentiating the efficacy of checkpoint blockade for non-immunogenic
tumors in mouse models.
Our field keeps
moving at a tremendous pace! If you'd like to join in to real-time
conversations about the latest research and you're active on social media, be
sure to take a moment to follow the official JITC Twitter handle, @jitcancer.
Best regards,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer
To view the entire February 2020 JITC Digest, please click here.
No comments:
Post a Comment